Topical Sirolimus for Darier Disease: a Multicentre Case Series and Immunostaining of Patient Biopsies Implicating mTORC1-associated Signalling

Clicks: 3
ID: 339790
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #417 of 420 articles by views in the british journal of dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 420 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
BACKGROUND: Darier disease (DD) is caused by pathogenic ATP2A2 variants that impair calcium homeostasis and keratinocyte adhesion. Responses to MEK inhibition support investigating additional pathway-directed treatments. Phosphorylated ribosomal protein S6 (pS6) Ser240/244 provides a downstream readout of mTORC1-associated signalling. OBJECTIVES: To describe outcomes with topical sirolimus 1% in DD and quantify epidermal pS6 Ser240/244 in paired lesional and non-lesional skin and healthy controls. METHODS: We retrospectively reviewed six patients treated with compounded sirolimus 1% cream, including three who received it as an add-on to ongoing systemic therapy. Treated areas were assessed using a retrospective Physician Global Assessment (PGA). Epidermal pS6 Ser240/244 immunofluorescence was quantified in nine pairs of lesional and non-lesional DD biopsies and nine healthy-control biopsies, using one aggregate value per biopsy. RESULTS: All five evaluable patients showed symptomatic and/or clinical improvement at a median PGA assessment time of 1 month (range 10 days to 6 weeks). One patient discontinued treatment after three days because of local intolerance, precluding efficacy assessment. Mean (SD) corrected pS6 intensity was 10.3 (2.0) arbitrary units in controls, 60.0 (53.5) in non-lesional DD and 99.5 (41.2) in lesional DD. Both DD groups differed from controls (Holm-adjusted P = 0.00185 and P = 0.0000823, respectively). Non-lesional values were heterogeneous, and the paired lesional-non-lesional difference was not significant (P = 0.36). CONCLUSIONS: Topical sirolimus showed promise as a local treatment, including as an adjunct for persistent lesions during systemic therapy. Increased epidermal pS6 provides complementary biological support for investigating mTORC1 inhibition in DD.
Reference Key
openalex_W7225985614 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors
Journal the british journal of dermatology
Year 2026
DOI
10.1093/bjd/ljag491
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.